Kathreen Jane A Lara, Steven Villaraza and Jose C Navarro
Posters-Accepted Abstracts: J Neurol Neurophysiol
Introduction: Vasospasm has been one of the major complications of aneurysmal SAH that gives poorer prognosis amongst
patients suffering from it. Although among cerebrovascular diseases, SAH accounts for only 2-5%, a higher mortality and
morbidity rate is accounted for by its complications, i.e. vasospasm.
Objective: This clinical trial aimed to determine the efficacy of oral nimodipine+cilostazol in reducing vasospasm following
aneurysmal SAH as compared to using nimodipine alone.
Design: This is an on-going prospective, randomized, single- blind, with intention-to-treat analysis. To have 95% chances, with
a significance level of 0.05, of detecting a 50% reduction in an incidence of cerebral vasospasm following aneurysmal SAH, a
minimum of 44 patients were required. As of the time being, only 14 patients were recruited.
Patients and randomization: A computer generated ID was drawn to identify to which treatment a patient will be grouped.
Intervention: Group A received nimodipine 60mg q4 x 21days alone, while Group B received nimodipine 60mg q4 x 21days
plus cilostazol 100mg q12 x 14days.
Monitoring and end points: Monitoring of the Lindegaard index (LI) from days 4 to 14 post ictus was done by a blinded
technician. An LI>3 indicates vasospasm (primary end point).
Preliminary results: This is an on-going study; hence statistical analyses have not been employed due to insufficient number
of samples recruited at the present time being. Initial findings revealed lower mean values for LI of patients taking both
nimodipine+cilostazol compared to those on nimodipine alone. Also, symptomatic vasospasm occurred more on those taking